Composition for astringin product
Provided is a composition for producing astringin among metabolites of polydatin, wherein the astringin may be mass-produced by oxidizing the polydatin using a CYP102A1 chimera and mutants thereof as a catalyst, the CYP102A1 chimera being produced by fusing a reductase domain of a wild-type CYP102A1 which is a bacterial cytochrome P450 enzyme, with a heme domain of a CYP102A1 mutant.
1. A composition for producing astringin from polydatin comprising a mutant of a CYP102A1 chimera,
wherein the mutant of the CYP102A1 chimera is F11L/F81I/Q110P/R190Q of the CYP102A1 chimera, and
wherein the CYP102A1 chimera consists of the amino acid sequence of SEQ ID NO: 18.
2. A kit for producing astringin from polydatin comprising a mutant of a CYP102A1 chimera and an NADPH-generating system,
wherein the mutant of the CYP102A1 chimera is F11L/F81I/Q110P/R190Q of the CYP102A1 chimera; and wherein the CYP120A1 chimera consists of the amino acid sequence of SEQ ID NO: 18.